(Reuters) – Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.

Companies with more exposure to the UK, the EU, South Korea, and Japan are likely in a better position, as these countries have secured favorable agreements that cap tariffs at around 15%.

However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.

Here’s what drugmakers are doing to mitigate supply-chain risks and reassure investors:

GSK

The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.

See Full Page